---
figid: PMC8065121__41467_2021_22407_Fig1_HTML
figtitle: 5-Carboxy-8-hydroxyquinoline (IOX1) potentiates chemo-immunotherapy
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC8065121
filename: 41467_2021_22407_Fig1_HTML.jpg
figlink: /pmc/articles/PMC8065121/figure/Fig1/
number: F1
caption: 'a IOX1 inhibits the histone demethylase Jumonji domain-containing 1A (JMJD1A)
  and thus downregulates its downstream β-catenin expression; b it downregulates P-glycoproteins
  (P-gp) and increases doxorubicin (DOX) concentration of cancer cells, facilitating
  the immunogenic cell death (ICD); c it downregulates tumour cells’ PD-L1 expression
  and thus disrupts the PD-1/PD-L1 pathway with T cells. d The synergy of the two
  effects enables its liposome formula (IOXL) combined with pegylated liposomal DOX
  (PLD), i.e. IPLD, to inhibit tumour growth. ER: endoplasmic reticulum, CRT: calreticulin,
  HMGB1: high mobility group box 1, ATP: adenosine triphosphate, iDC: immature dendritic
  cell, mDC: mature dendritic cell, CTL: cytotoxic T lymphocyte.'
papertitle: Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy.
reftext: Jing Liu, et al. Nat Commun. 2021;12:2425.
year: '2021'
doi: 10.1038/s41467-021-22407-6
journal_title: Nature Communications
journal_nlm_ta: Nat Commun
publisher_name: Nature Publishing Group UK
keywords: Cancer immunotherapy | Chemotherapy | Colorectal cancer | Metastasis | Tumour
  immunology
automl_pathway: 0.9423271
figid_alias: PMC8065121__F1
figtype: Figure
redirect_from: /figures/PMC8065121__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8065121__41467_2021_22407_Fig1_HTML.html
  '@type': Dataset
  description: 'a IOX1 inhibits the histone demethylase Jumonji domain-containing
    1A (JMJD1A) and thus downregulates its downstream β-catenin expression; b it downregulates
    P-glycoproteins (P-gp) and increases doxorubicin (DOX) concentration of cancer
    cells, facilitating the immunogenic cell death (ICD); c it downregulates tumour
    cells’ PD-L1 expression and thus disrupts the PD-1/PD-L1 pathway with T cells.
    d The synergy of the two effects enables its liposome formula (IOXL) combined
    with pegylated liposomal DOX (PLD), i.e. IPLD, to inhibit tumour growth. ER: endoplasmic
    reticulum, CRT: calreticulin, HMGB1: high mobility group box 1, ATP: adenosine
    triphosphate, iDC: immature dendritic cell, mDC: mature dendritic cell, CTL: cytotoxic
    T lymphocyte.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - crt
  - Calr
  - Dsp1
  - ATPsynbeta
  - Atpalpha
  - Rpn3
  - Dox-3
  - arm
  - egr
  - Pld
  - ctl
  - cutlet
  - CEBPD
  - CALCR
  - CALR
  - SLC6A8
  - HMGB1
  - ATP8A2
  - LMNA
  - GNPTAB
  - KDM3A
  - CTNNB1
  - TNF
  - IL6
  - GPLD1
  - PLD1
  - PLD2
  - PLD3
  - PLD4
  - PLD5
  - PLD6
  - CD274
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - ADAM11
  - CCL22
  - IL2
---
